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Previewsidentified (ALX/FPR2, ChemR23, BLT1,
and gpr32); but, clearly, elucidation of the
signaling pathways of these lipidmediators
will be a major future challenge. In any
event, the powerful anti-inflammatory and
proresolving properties of resolvins hold
therapeutic promise, underpinned by the
previous success story of eicosanoid-
modifying drugs (Samuelsson, 2012). To
fully explore the pharmacological utility of
such molecules, the precise molecular
signatures that confer bioactivity have to
be elucidated, as now achieved with RvD3
and AT-RvD3. In addition to its antipyretic
and analgesic effects, it is well established
that aspirin, due to its blockade of platelet
thromboxane synthesis (Hamberg et al.,
1975), exerts antihemostatic and antith-
rombotic effects, and low-dose aspirin is
currently used for prophylaxis of myocar-




140 Chemistry & Biology 20, February 21, 201tional beneficial effects, and the possible
role of this drug for prevention of a larger
spectrum of diseases, including cancer, is
currently being explored. AT-RvD3 and
other aspirin-triggered resolvins are likely
to be of importance in such contexts.
To use a metaphor proresolving lipid
mediators can be viewed as members of
an orchestra, where the cellular conductor
creates a resolution symphony specifically
tuned for the inflamed tissues to return to
homeostasis. With this perspective, Dalli
et al. (2013) have now defined two new
instruments RvD3 and AT-RvD3.
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The TetR family ofmicrobial transcription factors directly control the expression of a diverse range of genes in
bacteria by sensing specific ligands. In this issue of Chemistry & and Biology, Cuthbertson and colleagues
used phylogenomics to guide the identification of TetR-like protein cognate ligands and revealed a novel
inducible antibiotic resistance mechanism.TetR-family regulators (TFRs) are proteins
constitutedof twodomains:aDNA-binding
helix-turn-helix domain that is able to inter-
act with specific DNA motifs in operatora Sub-
.sites and a ligand binding (or
receptor) domain that
interacts with cognate small
organic molecules (Ramos
et al., 2005; Yu et al., 2010).
TFRs typically act as homodi-
meric transcriptional re-
pressors and control the
expression of diverse genes,
such as those that confer
antibiotic resistance (i.e.,
efflux pumps and modifyingenzymes), but also genes that direct the
biosynthesis of natural products and
morphogenesis or biofilm formation, to
mention a few. TFRs are widespread inbacteria and many of them repress the
transcription of genes that confer resis-
tance to the molecule sensed by the TFR
itself (Ramos et al., 2005). For instance,TetR senses the antibiotic
tetracycline and represses
the expression of tetA, which
encodes for a tetracycline
efflux pump, in the absence
of tetracycline as shown in
Figure 1 (Orth et al., 2000).
The set of genes regulated
by TFRs is only known in
a limited number of cases. In
some systems, the regulatory
network is relatively complex
Figure 2. Alternative Mechanisms of Antibiotic Resistance
Developed by Microorganisms
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Previewsand TFRs respond to signaling
molecules (such as gamma-
butyrolactones or furans) that
trigger the production of
various natural products
through a series of regulatory
cascades (Corre et al., 2008;
O’Rourke et al., 2009).
Astonishingly, TFR cognate
ligands are unknown for the
vast majority of TFRs. In this
issue of Chemistry & Biology,
Cuthbertson et al. (2013)
used phylogenomics to build
a global relational tree, in-
cluding 65 known ligands
and over 4,000 TFRs, in order
to guide the identification of
cognate ligands for ‘‘orphan’’
TFRs (Eisen, 1998).
One of the main challenges
remains the isolation and
structure elucidation of novelligands to start populating parts of the
tree that are currently empty. However,
the approach described and exploited by
Cuthbertson et al. (2013) is invaluable to
predict candidate ligands (basedonknown
ones) and guide the search for cognate
ligands. Importantly, this strategy will
become increasingly effective as the
number of novel characterized ligands
increases. The global relational tree re-
ported in the featured paper already offers
many hypotheses that need to be tested
experimentally. Several strategies to
isolate and identify novel ligands have
previously been developed. For instance,
tagged recombinant TFRs can be immobi-
lized and ligand binding can be investi-
gated by incubation with metabolites from
culture media or with synthetic molecules.
Alternatively, the use of gene reporter
systems based on individual TFR and
reporter genes under the control of the
specific target operator for a particular
TFR can guide the isolation of novel
ligands.Structural elucidationof thenatural
products isolated from culture media can
then be carried out using advanced analyt-
ical chemistry techniques (high resolution
mass spectrometry and nuclear magnetic
resonance spectroscopy).
Analysis of the genetic context of TFR
genes was, until now, the best predictive
tool available, because TFR ligands are
often related to the gene(s) regulated
(Ahn et al., 2012). Phylogenomics
brings an additional predictive power tothe search for missing TFR ligands. The
number of solved three-dimensional
structures of TFR family members bound
to their cognate ligand is still too few to
significantly contribute in developing
further predictive tools, but this situation
should improve as further structures
become available (Le et al., 2011).
In addition to being essential for the
understanding of microbial signaling and
communication, many of TFR regulatory
systems could be developed as inducible
expression systems for prokaryotic or
eukaryotic cells and represent invaluable
tools for systems and synthetic biology
studies.
As previously mentioned, many TFRs
regulate the expression of genes that
provide antibiotic resistance to bacteria
(pathogenic or not). Horizontal gene
transfer can result in these genes
spreading into human pathogens and
provides these bugs with multidrug resis-
tance (D’Costa et al., 2011).
TFRs permit the microorganisms to
express transcripts of the resistance
genes (and proteins) only when they are
required: in other words, when the toxic
molecules are present in their environ-
ment. This adaptive response is mediated
by the ligand binding domain of TFRs,
which responds to specific antimicrobials
at sub-inhibitory concentration. Many
important antibiotic resistance mecha-
nisms, such as biosynthesis of a modified
peptidoglycan, which is the target of theChemistry & Biology 20, February 21, 2013 ª2013 Elseglycopeptide antibiotic van-
comycin, are known to be
inducible (Hong et al., 2004).
The most obvious mecha-
nisms of resistance to antimi-
crobials involve modifying the
target (e.g., vancomycin), in-
activating the antibiotics or
preventing access to the
target by blocking cell perme-
ability, or actively exporting
the toxic molecules (Figure 2).
Various classes of enzymes
are able to inactivate toxic
molecules by catalyzing reac-
tions such as reduction/oxida-
tion (e.g., tetracyclines),
hydrolysis (e.g., b-lactams), or
other chemical modifications
of the toxic molecules such
as acetylation, phosphoryla-
tion, nucleotidylation,orglyco-
sylation. Every one of theseresistance mechanisms can potentially be
constitutively expressed or inducible.
In addition to completing the challenge
of identifying the cognate ligand for
a specific TFR (KijR), Cuthbertson et al.
(2013) revealed a novel inducible antibiotic
resistance mechanism. The regulation of
the expression of the resistance gene kijX
was investigated, and the recombinant
enzyme KijX was characterized. This
enzymewas foundtocatalyze thedeglyco-
sylation of the antibiotic kijanimicin, which
results in making this antibiotic inactive.
This is the first example of antibiotic resis-
tance by deglycosylation. Interestingly the
anticancer agent doxorubicin has also
recently been shown to be inactivated by
deglycosylation; in that case, a different
class of enzymes from the glycosyl hydro-
lase KijX responsible for kijanimicin inacti-
vation is involved (Westman et al., 2012).
Understanding resistance mechanisms
most often gives an insight into themolec-
ular mode of action of antimicrobials
and could result in developing further
strategies to combat multidrug resistant
bacteria, such as using a combination of
antibiotics with different targets or antibi-
otic derivatives with similar structures
but chemical bond(s) resistant to enzy-
matic hydrolysis.REFERENCES
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Ark1, the unique Aurora kinase in Schizosaccharomyces pombe, regulatesmultiple aspects of mitosis. In this
issue ofChemistry & Biology, Kawashima and colleagues report the discovery and validation of a fungal Ark1
inhibitor, which they employ to evaluate the mitotic outputs of endogenous Ark1 signaling.Mitosis is a prime example of a dynamic
cellular transition orchestrated bymultiple
protein kinase activities. Untanglingwhich
kinases do what, and when and where
they do it, represents a major challenge
in the field. Unfortunately, we currently
lack validated tools to distinguish
between on/off (switch-like) and wide-
range (rheostat-like) catalytic outputs of
kinases, the latter potentially enabling
diverse cellular outputs to be spatially
and temporally programed using a single
enzyme. This question is pertinent to
cell-cycle regulated kinases such as
Mps1, Aurora, and Polo-like kinases,
which are reversibly activated during
mitosis and integrate the sequential steps
required to successfully execute cell divi-
sion (Bayliss et al., 2012). One technique
for studying kinase biology involves the
exploitation of small molecule inhibitors,
whose rapid and often reversible binding
to kinases can be successfully harnessed
to probe signaling in cells. However, to be
really effective as biological tools, these
compounds must inhibit a cellular kinase
target in a specific and/or highly tractable
fashion (Cohen, 2009). Unfortunately,
most protein kinase inhibitors are falliblein this regard, due to high promiscuity
toward multiple ATP-binding sites and
the complex challenges associated with
unequivocal ‘‘on-target’’ validation, which
is a widespread problem in molecular
pharmacology. However, because pro-
tein kinases contain prominent amino
acid loci whose physiochemical proper-
ties create ‘‘selectivity filters’’, the dis-
criminatory capacity of many kinases for
diverse compounds targeting the ATP
site can be rationalized in a rather general
manner (Balzano et al., 2011; Bishop
et al., 2000; Eyers et al., 1998; Huang
et al., 2010). Four key positions bordering
the hinge region of protein kinases dictate
resistance or sensitivity to differing
ligands, and we term these amino acids
a ‘‘resistance tetrad’’ (Figure 1). Critically,
catalytically silent mutation of these resi-
dues can create resistant (or sensitized)
versions of kinases, permitting pheno-
typic effects observed with small mole-
cules to be validated with high levels of
certainty (Balzano et al., 2011; Eyers
et al., 1999; Scutt et al., 2009; Sloane
et al., 2010; Zunder et al., 2008).
The fission yeast Schizosaccharomy-
ces pombe is a valuable laboratory modelfor studying mitosis. Unfortunately, it is
resistant to many small molecules that
traverse the cell membrane of vertebrate
cells, potentially restricting its usefulness
for mechanistic drug discovery. Two
recent studies reported in Chemistry &
Biology by the Nurse and Kapoor labora-
tories have addressed this major obstacle
to progress in the field. In their initial
paper, Kawashima et al. (2012) described
the generation of a drug-sensitive fission
yeast strain (MDR-sup) in which fivemulti-
drug resistance (MDR) genes were
deleted, enhancing the ability of small
molecules to accumulate and induce
quantifiable biological effects. Hot on the
heels of this advance, the same group
(Kawashima et al., 2013; in this issue
of Chemistry & Biology) reports the
discovery of Arkin-1 (Figure 1A), an inhib-
itor of the endogenous S. pombe kinase
Ark1, a key regulator of mitosis related
to vertebrate Aurora kinases (Petersen
et al., 2001). By combining a small mole-
cule screen with chemical genetics in
Ark1 wild-type and drug-resistant iso-
genic strains, evidence for rheostat-like
behavior of Ark1 during mitosis was
uncovered, which is consistent with the
